Factor IX product launched in US

Print Friendly, PDF & Email


Rebinyn vials
Photo from Novo Nordisk
The recombinant, GlycoPEGylated coagulation factor IX product Rebinyn® is now available in the US for the treatment of patients with hemophilia B. Last May, Rebinyn was approved by the US Food and Drug Administration for on-demand treatment and control of bleeding episodes as well as perioperative management... [Read Article]
Print Friendly, PDF & Email

IV bevacizumab improves severe bleeding in HHT

Print Friendly, PDF & Email


Mucocutaneous telangiectasias
at baseline (left) and after
3 doses of IV bevacizumab
Photo courtesy of
Mayo Clinic Proceedings
Intravenous (IV) bevacizumab “dramatically” improves severe bleeding associated with hereditary hemorrhagic telangiectasia (HHT), according to researchers. In a retrospective study, HHT patients with severe bleeding had a substantial reduction in nose bleeds and gastrointestinal (GI)... [Read Article]
Print Friendly, PDF & Email

CHMP recommends approval of emicizumab

Print Friendly, PDF & Email


Emicizumab (Hemlibra)
Photo from Business Wire
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of emicizumab (Hemlibra®), a bispecific factor IXa- and factor X-directed antibody. The recommendation is for emicizumab to be used as routine prophylaxis in patients of all ages who have hemophilia A with... [Read Article]
Print Friendly, PDF & Email

Real-world data show risk of major bleeding, stroke with NOACs

Print Friendly, PDF & Email


Dabigatran
Photo courtesy of
Boehringer Ingelheim
A real-world analysis has quantified the risks of stroke and major bleeding in patients with non-valvular atrial fibrillation (NVAF) starting treatment with novel oral anticoagulants (NOACs). The data showed that patients receiving dabigatran had a significantly lower rate of major bleeding but a similar rate of stroke... [Read Article]
Print Friendly, PDF & Email

Low inhibitor rate observed in PUPs with hemophilia A

Print Friendly, PDF & Email


Antihemophilic factor
Researchers have observed a low inhibitor rate in previously untreated patients (PUPs) with severe hemophilia A who received treatment with Octanate®. The study included 51 PUPs who received octanate, a plasma-derived, von Willebrand factor-stabilized coagulation factor VIII (FVIII) concentrate. Five of these patients (9.8%) developed FVIII inhibitors, all of whom were... [Read Article]
Print Friendly, PDF & Email